Ramelteon

Drug Profile

Ramelteon

Alternative Names: Ramelteon SL; Ramelteon sublingual; Rozerem; TAK-375; TAK-375SL

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Developer Sun Pharmaceutical Industries; Takeda
  • Class Anxiolytics; Indenes; Sleep disorder therapies; Small molecules
  • Mechanism of Action Melatonin MT1 receptor agonists; Melatonin MT2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Insomnia
  • Discontinued Alzheimer's disease; Bipolar depression; Bipolar disorders; Circadian rhythm sleep disorders

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Insomnia(In adolescents, In children) in USA (PO, Tablet)
  • 11 Sep 2015 Discontinued - Phase-III for Bipolar depression (Adjunctive treatment) in USA, United Kingdom, Poland, Bulgaria, Czech Republic, Germany, Romania, Russia, Serbia, Ukraine, Argentina, Canada, Chile, Colombia, Mexico (Sublingual) before 15 May 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top